Hosted on MSN28d
BRCA1 gene mutations may not be key to prostate cancer initiation, as previously thought
Germline BRCA 1 and BRCA 2 test results were available for all 450 men. These revealed 27 germline BRCA2 variants (6%), but only two germline BRCA1 variants (0.5%), and one of these probably wasn ...
Oncology Nursing News9h
Supporting Patients Through New Breast Cancer Treatments
The presence of biomarkers, even in small amounts, can shape the course of treatment for a patient, says Andy Guinigundo, MSN, RN, CNP, ANP-BC.
CURE7d
Understanding Genetic and Genomic Testing in Breast Cancer
Genetic and genomic testing guide breast cancer risk assessment and treatment, as discussed by Dr. Mark Robson at the Miami ...
Frontiers4d
BRCA mutations and Homologous Recombination Deficiency (HRD) testing in ovarian cancer
Ovarian cancer (OC) is the fifth most common cause of cancer-related mortality worldwide and represents the leading cause of death for gynecological malignancies. Nevertheless, over the last years, ...
News Medical1mon
Study challenges role of BRCA1 mutation in prostate cancer initiation
This indicates that BRCA2 variants, somatic and germline, have a major role in prostate cancer progression affecting at least 1 in 10 carriers with the disease, say the researchers. BRCA1 variants ...
MedPage Today8d
Second Primary Cancer Risks After Breast Cancer in BRCA1 and BRCA2 Pathogenic Variant Carriers
Opens in a new tab or window We followed 25,811 females and 480 males diagnosed with BC and tested for germline BRCA1/BRCA2 PVs in NHS Clinical Genetics centers in England between 1995 and 2019 ...
Medscape3mon
PARP Inhibitors: The Journey From Research Hypothesis to Clinical Approval
All have shown proof of concept success in germline BRCA mutation carriers. Furthermore, several combinations with other drugs are being investigated. Clinical PARP inhibitors: where are we now?
MedPage Today1mon
BRCA1 Contribution to Prostate Cancer Called Into Question
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Mutations in ...
Seeking Alpha5d
MYGN Myriad Genetics, Inc.
and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination ...
EurekAlert!1mon
BRCA1 gene mutations may not be key to prostate cancer initiation, as previously thought
These revealed 27 germline BRCA2 variants (6%), but only 2 germline BRCA1 variants (0.5%), and one of these probably wasn’t the driver as an ATM mutation was also present, note the researchers.
Medical Xpress29d
BRCA1 gene mutations may not be key to prostate cancer initiation, as previously thought
Among those in this group who weren't tested, based on high risk—age or family history—at least 18 (just over 5%) had a germline BRCA2 variant, but only one had a germline BRCA1 (0.3%) variant ...